Antibody-Drug Conjugate (ADC) CROs
32 published
32 published CROs match Antibody-Drug Conjugate (ADC).
Locations in this set include United States, China, United Kingdom, Canada, France, and Australia.
Capabilities that show up most often in this set: Bioanalysis, Biomarker Assays, In Vitro Pharmacology, Discovery Research, and Preclinical In Vitro Studies.
Matching companies
Pharma InventorVancouver-based preclinical drug discovery CRO offering medicinal chemistry, custom synthesis, LC-MS/MS bioanalysis, high-throughput screening and ADC development for pharma and biotech teams. Lists 6,000+ sq ft of research facilities and in-house 400 MHz NMR.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
PozeSCAF Inc.Preclinical drug discovery CRO combining proprietary generative AI platform AxDrug with computational chemistry, synthetic chemistry, and in vitro biology to accelerate hit discovery and lead optimization for biotech and pharma clients.
Proone LabsProone Labs provides preclinical pharmacology, drug discovery, and regulatory support services to biotech startups, traditional pharma, and in-silico companies. The team has delivered 30+ assays, 50+ cell lines, and supported 4 FDA drug approvals across multiple therapeutic areas.
Reaction BiologyGlobal preclinical CRO specializing in kinase drug discovery, cell-based assays, in vivo pharmacology, and immuno-oncology with 1,000+ cell lines and hundreds of validated protein targets across US and EU facilities.- STC BiologicsBoutique biologics CDMO with a Speed-to-Clinic platform spanning royalty-free cell line development through cGMP drug substance, in as little as 12 months. Runs a single-use mammalian GMP suite in Newton, MA for antibody, bispecific, and ADC programs.
Sword BioBioanalytical CRO offering ligand binding assay development, PK, immunogenicity (ADA and NAb), and custom biomarker assays under non-GLP, spirit-of-GLP, and GLP conditions. Supports clients from discovery through clinical Phase IV.
Syneos HealthGlobal CRO with 26,000+ employees offering integrated clinical development, regulatory affairs, and commercialization services. Helped develop or commercialize 96% of FDA-approved oncology drugs and 93% of EMA-authorized oncology products in the last five years.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
TRiCBIOTRiCBIO provides human organoid research services for efficacy, safety, mechanism and immune-context studies using PDO 2.0 and ALI platforms, supporting biopharma and CRO teams in candidate evaluation and translational research.
Worldwide Clinical TrialsFull-service global CRO with 30+ years of therapeutic expertise, delivering personalized clinical trial support across rare disease, cardiovascular, cell & gene therapy, oncology, and neuroscience.
WuXi AppTecGlobal CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Markdown mirror: /modalities/antibody-drug-conjugate.md